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Abstract 
  
Context and objective: To evaluate if YKL-40 can provide prognostic information in 
patients with ischemic heart failure (HF) and identify patients who may benefit from statin 
therapy. Materials and Methods: The association between serum YKL-40 and predefined 
outcome was evaluated in 1344 HF patients assigned to rosuvastatin or placebo. Results: 
YKL-40 was not associated with outcome in adjusted analysis. In YKL-40 tertile 1, an effect 
on the primary outcome (HR 0.50, p=0.006) and CV death (HR 0.54 p=0.040) was seen by 
rosuvastatin in adjusted analysis. Conclusions: A beneficial modification of outcome was 
observed with statin therapy in patients with low YKL-40 levels.   
 
Clinical Trial Registration Information: URL: http://www.clinicaltrials.gov. Unique 
identifier: NCT00206310.  
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Introduction 
Despite major therapeutic advances over the past three decades, the prognosis for patients 
with heart failure (HF) remains poor and the need for new treatments remain apparent 
(Braunwald 2013;Mosterd et al. 2007). Biomarkers may help in developing new treatments 
either by targeting therapies to patients at highest risk or by identifying specific 
pathophysiological pathways responsible for disease progression (Bartunek 2009;Dalzell et 
al. 2014). YKL-40 is a plasma glycoprotein primarily secreted by activated macrophages, but 
may also be produced by neutrophils, vascular smooth muscle cells and chondrocytes in the 
presence of inflammation (Johansen 2006;Kastrup 2012). Although the precise functions of 
YKL-40 are not identified, it is suggested to play a role in inflammation, fibrosis and 
extracellular matrix (ECM) remodeling (Johansen 2006;Volck et al. 1998). Several studies 
have demonstrated increased systemic levels of YKL-40 in patients with ischemic heart 
disease (Harutyunyan et al. 2013;Kastrup et al. 2009;Kucur et al. 2007;Michelsen et al. 
2010;Wang et al. 2008), with particularly high levels following acute myocardial infarction 
(MI), and these have been correlated with disease progression and severity (Hedegaard et al. 
2010;Kucur et al. 2007). 
In a cross sectional study Mygind et al. demonstrated lower serum levels of YKL-40 
in statin treated, compared with non-statin treated, coronary artery disease patients (Mygind 
et al. 2011), although the effect of a statin on YKL-40 levels has not been examined in a 
placebo-controlled randomized controlled trial. Recently, in a large cohort (n=717) of HF 
patients with mixed etiology, Harutyunyan et al. reported that elevated levels of serum YKL-
40 were associated with all-cause mortality (Harutyunyan et al. 2012). 
Based on the emerging importance of YKL-40 in the progression of ischemic heart 
disease, 
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including its role in inflammation, fibrosis and ECM remodeling, we hypothesized that YKL-
40 could predict adverse outcomes in patients with ischemic HF. This was assessed in  the 
Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA) population, a 
contemporary cohort of older patients with chronic systolic ischemic HF randomly assigned 
to statin therapy (rosuvastatin) or placebo in a double-blind fashion (Kjekshus et al. 2007). 
Our goals were to determine whether: i) YKL-40 provides independent prognostic 
information in this population ii) statins regulate YKL-40 levels and iii) YKL-40 levels could 
be used to identify a subgroup of patients who may benefit from statin therapy 
 
Methods 
Patients and Study Procedures 
The design and principal findings of CORONA have been reported in detail (Kjekshus et al. 
2007). Clinical Trial Registration Information: URL: http://www.clinicaltrials.gov. Unique 
identifier: NCT00206310. Briefly, patients ≥60 years of age with chronic HF attributed to 
ischemic heart disease, defined as (i) medical history or ECG signs of MI or (ii) other data 
suggesting an ischemic etiology (e.g. wall motion disturbances on echocardiography or 
history of other occlusive atherosclerotic disease [i.e. earlier stroke, intermittent claudication, 
percutaneous coronary intervention (PCI)]), who were in New York Heart Association 
(NYHA) class II-IV, with a LV ejection fraction (LVEF) ≤40% (≤35% if NYHA II), were 
eligible for inclusion. Patients were randomly assigned to rosuvastatin 10 mg/day or 
matching placebo, once-daily. The trial complied with the Declaration of Helsinki and was 
approved by the Ethics Committees of the participating hospitals. All patients provided 
written informed consent. Ethics committee/institutional review board: Regional 
Etiksprövningskommitten I Göteborg, Sahlgrenska Akademin, Mediniargatan 3, Plan 5. 
Diary number: Ö284-03. The name of the ethics committees from any of the participating 
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hospitals can be provided on request. Name of study locations can be found in (Askevold et 
al. 2015). The present study was an optional, predefined sub-study of the main CORONA 
trial conducted at 378 participating hospitals, focusing on inflammatory biomarkers, which 
included patients from centers capable of collecting the necessary blood samples. 
Compliance, side-effects and dropouts in the CORONA trial have been reported previously 
(Kjekshus et al. 2007). 
Study outcomes and definitions  
The primary predefined outcome was the composite of death from cardiovascular (CV) 
causes, non-fatal MI, and non-fatal stroke, analyzed as time to the first event. The secondary 
predefined outcomes were (analyzed as time to first event) a) all-cause mortality, b) CV 
mortality (including cause-specific CV death), c) coronary endpoint (defined as sudden death, 
fatal or non-fatal MI, performance of PCI or coronary artery bypass graft surgery [CABG], 
ventricular defibrillation by an implantable cardioverter-defibrillator [ICD], resuscitation 
from cardiac arrest, or hospitalization for unstable angina pectoris), d) the number of 
hospitalizations for CV causes, and e) hospitalization for worsening HF (WHF). The 
definition and adjudication of all outcomes have been described in detail previously, as have 
data on C-reactive protein (CRP) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) 
(Cleland et al. 2009;Kjekshus et al. 2007;McMurray et al. 2009;Wedel et al. 2009). 
 
Blood sampling and biochemical analyses 
YKL-40 was measured from blood samples taken after an overnight fast. All other blood 
samples were non-fasting and analyzed on fresh samples at a central laboratory (Medical 
Research Laboratories, Zaventem, Belgium). NT-proBNP was analyzed using commercially 
available assay (Roche Diagnostics, Basel, Switzerland). An immunonephelometric high-
sensitivity method was used to measure CRP (Dade Behring, Atterbury, UK; sensitivity 0.04 
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mg/L). Serum YKL-40 was measured by enzyme immunoassay (R&D Systems, Minneapolis, 
MN) with intra- and inter- assay coefficients of variation <10%. To validate this assay, 
another commercial assay from Quidel (Quidel, San Clara, CA) was used. 
 
Statistical analysis  
For comparing two groups, the Mann-Whitney U test was used. Kaplan-Meier curves were 
constructed to visualize and evaluate (log rank test) differences in survival. Trends across 
tertiles of YKL-40 were tested using the Cuzick extension of the Wilcoxon rank-sum test. A 
restricted cubic spline (RCS) analysis with three knots was undertaken on the outcome all-
cause mortality to assess linearity of risk. Survival analyses were performed using the Cox 
proportional hazard regression models to estimate hazard ratios (HRs) and 95% confidence 
intervals (CIs) for YKL-40 included as log-transformed standardized (per standard deviation) 
continuous variables at baseline or as nominal changes in a version of the model developed 
previously for the full CORONA population (Wedel et al. 2009), which included mainly 
clinical variables at step one (LVEF, NYHA class, age, body mass index [BMI], diabetes 
mellitus [DM], sex, intermittent claudication, and heart rate [HR]). At step two, estimated 
glomerular filtration rate (eGFR) and apolipoprotein (Apo) B/ApoA-1 ratio were included in 
the model, and finally, at stage 3, the log-transformed serum concentrations of NT-proBNP 
and CRP were included. Harrel’s C-statistic was calculated for all endpoints using the full 
model with and without YKL-40, and the difference between the C-statistics was estimated. 
We implemented a jack-knife cross-validation approach to correct for over-optimism 
associated with validating a model in the same material from which it is developed. In this 
approach predictions for each observation were obtained from models developed on the 
remaining observations. These cross-validated probabilities were used to calculate jack-knife 
C-statistics. Calculation of the net reclassification improvement (NRI) is increasingly being 
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used to evaluate the prognostic usefulness of a biomarkers (Pencina et al. 2010). When no 
established risk categories exist, the use of a category-free NRI has been advocated (Pencina 
et al. 2011). We therefore calculated the category-free NRI after adding YKL-40 to the full 
model. Confidence intervals and p-values for NRI were determined by boot-strapping with 
2000 repetitions. A two-sided p-value <0.05 was considered to be significant, except for 
interaction terms, for which p-values <0.10 were accepted (Zelen 1971). All statistical 
analyses were performed using STATA version 11 for Windows (StataCorp, College Station, 
TX).  
 
Results 
Of the 5,011 patients enrolled in the CORONA study, a measurement of YKL-40 levels was 
available in 27% (n=1344). Compared with the entire CORONA population, the patients in 
the present study were slightly younger, were more often in NYHA class III, more frequently 
had a history of myocardial infarction and hypertension and had a higher mean LVEF, 
diastolic blood pressure, and cholesterol level. Conversely, the proportion with diabetes 
mellitus and a pacemaker was smaller (Table 1). Patient characteristics according to tertile 
values of YKL-40 are shown in Table 1. Patients with higher serum levels of YKL-40 were 
more likely to be older and have a lower BMI, diastolic blood pressure and total- and LDL 
cholesterol. They were also more likely to have atrial fibrillation and worse kidney function.  
NT-proBNP and CRP concentrations were significantly higher in patients with higher YKL-
40 levels. Stepwise linear regression identified higher age (per decade β±SE 28.5±6.1, 
p<0.001), NT pro-BNP (log 19.6±3.3, p<0.001) and CRP levels (log 26.3±3.4, p<0.001), and 
lower total cholesterol concentration (-8.4±3.9, p=0.029), as the strongest predictors of YKL-
40 levels.  
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Association between serum YKL-40 levels and clinical outcomes     
During a median follow-up of 955 (817, 1103) days, 396 patients died. Kaplan-Meier plots 
for the primary end point, all-cause- and CV mortality and the coronary endpoint revealed a 
poorer outcome for patients in the two top tertiles of YKL-40 compared to the bottom tertile 
(Figure 1). Unadjusted Cox proportional hazard regression models displayed significant 
associations between log-transformed standardized baseline YKL-40 (log/SD) levels and all 
the endpoints (Table 2). These associations were moderately attenuated but significant for all 
outcome after adjustment for demographics and baseline characteristics (Step 1, e.g. LVEF, 
NYHA, age, BMI, diabetes) and traditional risk markers (Step 2: ApoB/ApoA-1 ratio and 
eGFR) except sudden death. However, after adjusting for NT-proBNP and CRP (Step 3), the 
association between YKL-40 and all outcome variables was markedly attenuated and not 
significant. The primary endpoint in adjusted analysis without NT-proBNP and CRP but with 
YKL40 had a c-statistic of 0.68, while with NT-proBNP and CRP but without YKL40, the C-
statistic is 0.72 (p<0.001). Use of diuretics (p=0.66) or digitalis (p=0.20) had no impact on 
the primary endpoint. 
 
Change in levels of YKL-40 levels during rosuvastatin treatment 
A small increase in YKL-40 levels was observed in the placebo group (median [25th, 75th 
percentile]: baseline 169 [110,288] and 3 months 183 [113,279] p=0.017), while a minor 
decrease was found during rosuvastatin treatment (baseline 180 [117,291] and 3 months 175 
[111,274] p=0.053) resulting in a modest but significant difference in change from baseline 
between the treatment arms (placebo: +4 [-28,46] vs. rosuvastatin: -3 [-47,34] p=0.002). 
However, the change in YKL-40 was not related to outcome (data not shown). Statins 
decreased LDL levels as described previously (Kjekshus et al. 2007). However, there was no 
difference in the decrease in LDL-cholesterol across YKL-40 tertiles in either treatment arm 
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(p=0.84 comparing the change across tertiles). 
 
Interactions between treatment and serum levels of YKL-40 and outcome 
Interactions between treatment and serum levels of YKL-40 and outcome are depicted in 
Figure 2 which shows Cox adjusted placebo/rosuvastatin HRs (full adjustment including 
hsCRP and NT-proBNP) for each tertile of YKL-40. The interaction by treatment p-values 
for YKL-40 was significant for the primary endpoint, CV mortality, mortality from WHF and 
total mortality (with p<0.1 considered significant for an interaction). Further analysis 
revealed that while use of rosuvastatin was not associated with the primary endpoint or CV 
mortality in those with intermediate of high YKL-40 levels, the incidence of these endpoints 
was significantly reduced by rosuvastatin in tertile 1 (Figure 2). Thus, the treatment benefit 
for the primary endpoint in T1 of BNP (Wald 7.1, HR 0.45 (0.25-0.81) p=0.008) and T1 of 
YKL-40 (Wald 7.2, HR 0.50 (0.30-0.83) p=0.006) are comparable. 
 When including initial cholesterol levels in the fully adjusted analysis, the effect of 
treatment on the primary outcome (p=0.025); treatment effect in T1: HR 0.49 (0.29-0.85) 
p=0.011, and CV mortality (p=0.055); treatment effect in T1: HR 0.53 (0.29-0.98) p=0.044, 
was only marginally attenuated. As shown in Figure 3, the beneficial effect of rosuvastatin in 
YKL-40 tertile 1 was accompanied by a significantly larger decrease in total cholesterol, 
compared to tertile 3.  
 
Comparison of the YKL-40 assay 
A restricted cubic spline analysis of baseline YKL-40 concentration versus all-cause 
mortality confirmed the non-linearity of this relationship, with a linear increase in the first 
tertile, followed by flattening of the curve for tertiles 2 and 3 (Figure 4A). A previous study 
in patients with chronic HF of mixed etiology (n=717) demonstrated a linear increase in all-
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cause mortality across quartiles of YKL-40 using a different commercial EIA (Harutyunyan 
et al. 2012). To evaluate potential methodological differences between the two assays we 
analyzed 40 random serum samples with both assays. As shown in Figure 4B, there was a 
strong correlation between both assays (r=0.92, p<0.001). Our EIA gave values that were 
12% higher than the Quidel assay but after normalizing for this difference, a quartile analysis 
showed good correspondence between the two assays (Figure 4C). In an additional analysis 
of the relationship between YKL-40 quartile and outcomes in CORONA (Figure 4D), there 
was a similar pattern to that seen with tertiles, with leveling of the risk from quartile 2 
upwards and no gain in predictive power with increasing quartiles. Thus, the different 
association with outcome between the two studies is likely not due to methodological 
differences.  
 
Discussion 
In this retrospective sub-study of CORONA, we found that baseline levels of YKL-40 were 
not associated with clinical outcomes in patients with advanced, ischemic, systolic HF in 
adjusted analyses. However, rosuvastatin did seem to have beneficial effects in patients with 
low circulating levels of YKL-40 i.e. in the lowest tertile.  Thus, while baseline levels of 
YKL-40 may have limited use as a prognosticator in patients with HF, YKL-40 may be 
useful in identifying a subset of patients who may benefit from statin therapy, although this 
finding needs to be confirmed in a prospective controlled trial. 
YKL-40 seems to be a universal marker for non-specific disease as it is increased in 
multiple diseases with an element of inflammation and tissue remodeling (Johansen 
2006;Kastrup 2012). In a large study of the general population (n=8899), Johansen et al. 
demonstrated a strong association between increased circulating YKL-40 and risk of early 
death from CV diseases, cancer and other chronic inflammatory diseases (Johansen et al. 
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2010). Three previous studies have evaluated the association between YKL-40 levels and 
outcome in HF. In two smaller studies, Rathcke et al. (n=194) found no association with 
overall mortality or incident CV disease (Rathcke et al. 2010), while Bilim et al. (n=121) 
found that YKL-40 was an independent predictor of cardiac events (Bilim et al. 2010). 
However, by far the largest of these (n=717) demonstrated that YKL-40 was associated with 
all-cause mortality in HF patients, also after multivariable adjustment, including NT-proBNP 
and CRP (Harutyunyan et al. 2012). In our study YKL-40 was associated with multiple 
outcomes after adjustment for acknowledged clinical and some biochemical predictors. 
However, the associations were markedly attenuated and no longer significant following 
adjustment for CRP and NT-proBNP. Several recent studies demonstrate associations 
between circulating YKL-40 and the presence and extent of CAD (Harutyunyan et al. 
2013;Kastrup et al. 2009;Kucur et al. 2007;Wang et al. 2008), and one could anticipate that 
YKL-40 would be a particularly strong biomarker in ischemic HF. However, the mechanisms 
that promote plaque progression and progression of myocardial failure may be somewhat 
different. Moreover, the present study population was elderly patients with severe HF, 
representing a rather homogenous population narrow range of several demographics 
including age and kidney function and exclusive ischemic etiology, potentially contributing 
to differences between these studies. Also, in the CORONA population, NT-proBNP has 
proved to be a particularly strong prognosticator and is by far the strongest predictor of 
outcomes in this population (Wedel et al. 2009). Thus, YKL-40 may reflect a more general 
age-related disease progression independent of etiology.  
While rosuvastatin did not reduce the primary outcome in CORONA (Kjekshus et al. 
2007) and the role of statin therapy on HF is unclear (Gastelurrutia et al. 2013;von 2009), 
some biomarkers in this cohort have demonstrated an interaction with statin therapy and 
identified subgroups with beneficial treatment effects (Cleland et al. 2009;Gullestad et al. 
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2012;McMurray et al. 2009;Ueland et al. 2015).  Although only a minor treatment effect of 
statins on serum YKL-40 was observed, our study suggests that targeting HF patients with 
low levels of YKL-40 for statin treatment may improve certain outcomes. This is comparable 
to our findings for galectin-3 and the ECM proteoglycan biglycan, mediators involved in 
fibrosis and ECM remodeling (Gullestad et al. 2012;Ueland et al. 2015). We and others have 
previously shown that YKL-40 may reflect macrophage activation, tissue remodeling and 
fibrosis (Johansen 2006;Michelsen et al. 2010;Volck et al. 1998) which all characterize the 
myocardium in ischemic cardiomyopathy and are associated with elevated levels of ECM 
markers (Dalzell et al. 2014;Deardorff et al. 2009). Although YKL-40 is expressed in 
multiple tissues, it is tempting to hypothesize that low YKL-40 levels may identify patients 
with a modifiable disease course while patients with higher circulating levels might have 
such increased expression within the myocardium that they have irreversible tissue 
remodeling. However, as this is a clinical study and associations do not imply a causal 
relationship, there could be a random element in our findings. Furthermore, as NT-proBNP  
is a widely available standardized analysis, the clinical usefulness of these findings are at 
present unknown. 
 Certain strengths of this study include a large sample size and a large number of end 
points. However, for some subgroup analyses, fewer end points might explain the lack of 
significance, and these data should be interpreted cautiously. Moreover, the study was 
performed in trial patients over 60 years who have less comorbidity. Thus, the results cannot 
necessarily be applied to the general HF population. Also, the patients included had systolic 
HF and our findings might not apply to patients with preserved LVEF. 
 
Conclusion 
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In conclusion, circulating levels of YKL-40 had limited predictive value in patients 
with chronic HF of ischemic cause. While there was only a minor effect of rosuvastatin on 
serum YKL-40 concentration, our results suggest that statin therapy might improve clinical 
outcomes in HF patients with low levels of YKL-40.  
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Table 1. clinical and biochemical baseline characteristics stratified by tertile values of YKL-40 
 
Total 
Corona 
n=5011 
Substudy 
n=1344 
Tertile 1 
(<133) 
Tertile 2 
 (133-243) 
Tertile 3 
 (>243) 
P-trend 
Age, y 72.7±7.1 71.8 ±6.9 70.0±6.5 72.5± 6.7 73.3±7.0 <0.000 
Female Sex, n (%) 1180 (24) 335 (22.6) 115 (25.7) 98 (21.9) 93 (20.8) 0.080 
NYHA class, n 
     
0.068 
II 1857 471 (31.8) 160 (35.7) 128 (28.6) 134 (29.9) 
 
III 3081 994 (67.1) 284 (63.4) 312 (69.6) 310 (69.2) 
 
IV 73 17 (1.1) 4 (0.9) 8 (1.8) 4 (0.9) 
 
Ejection Fraction 0.31±0.06 0.32±0.07 0.32±0.07 0.32±0.06 0.31±0.07 0.059 
Body mass index 27.2±4.5 27.2±4.6 27.6±4.6 27.2±4.7 26.9±4.5 0.035 
Systolic BP, mm Hg 129.3±4.5 130 ± 16.1 129 ±14.5 130 ±17.0 129 ±16.5 0.590 
Diastolic BP, mmHg 76.2±8.9 77 ±8.9 78±8.9 77±8.8 76±9.0 0.010 
Heart rate, beats per/min 71±11.2 71±10.7 71±11.2 71±11.0 71±10.1 0.217 
Current smoker 528(10.5) 165 (11.1) 49 (10.9) 55 (12.3) 50 (11.2) 0.916 
Medical history 
      
Myocardial infarction 3006 (60.0) 939 (63.4) 296 (66.1) 275 (61.4) 278 (62.1) 0.213 
PCI, PTCA or CABG 1229 (24.5) 321 (21.7) 85 (19.0) 102 (22.8) 104 (23.2) 
 
Hypertension 3175 (63.4) 1031 (69.6) 319 (71.2) 310 (69.2) 308 (68.8) 0.424 
Diabetes Mellitus 1477 (29.5) 392 (26.5) 108 (24.1) 130 (29.0) 120 (26.8) 0.365 
Atrial fibrillation 1194 (23.8) 325 (21.9) 77 (17.2) 96 (21.4) 119 (26.6) 0.001 
Stroke 624 (12.5) 179 (12.1) 53 (11.8) 65 (14.5) 46 (10.3) 0.475 
Laboratory measurements 
      
Cholesterol,Mmol/L 
      
Total 5.2±1.1 5.2±1.09 5.3±1.07 5.2±1.07 5.1±1.08 0.000 
LDL 3.6±0.9 3.7±0.98 3.8±1.01 3.6±0.93 3.5±0.92 0.000 
HDL 1.2±0.35 1.2±0.35 1.2±0.33 1.2±0.34 1.2±0.37 0.834 
Triglycerides, Mmol/L 2.00±1,28 2.0±1.37 1.9±1.13 2.0±1.40 2.1±1.38 0.057 
ApoB/ApoA-1 ratio 0.87±0.25 0.88±0.25 0.91±0.25 0.86±0.24 0.87±0.26 0.061 
eGFRMDRD 57±14.4 58±14.4 61±13.4 57± 13.1 55±15.7 0.000 
NT-proBNP,  pM 173(73,368) 158(61,342) 100(40,234) 185 (80,338) 206 (91,472) 0.000 
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CRP, mg/L 3.5 (1.6,7.4) 3.6(1.6,7.6) 2.8 (1.2,5.3) 3.8 (1.8,7.7) 4.8 (2.1,11.4) 0.000 
Current medication 
      
Diuretic 
     
0.010 
Thiazide or loop 3977 (79.4) 1113 (75.1) 343 (76.6) 335 (74.8) 341(76.1) 
 
Both 357 (7,1) 169 (11.4) 40 (8.9) 47 (10.5) 60 (13.4) 
 
Aldosteron antagonist 1906 (38.0) 544 (36.7|) 177 (39.5) 161 (35.9) 155 (34.6) 0.127 
ACE inhibitor 3981 (79.4) 1195 (80.6) 366 (81.7) 356 (79.5) 360 (80.4) 0.613 
ARB 637 (12.7) 150 (10.1) 46 (10.3) 39 (8.7) 50 (11.2) 0.127 
β-blocker 3722 (74.3) 1132 (76.4) 350 (78.1) 348 (77.7) 329 (73.4) 0.099 
Digitalis glycoside 1618 (32.3) 433 (29.2) 112 (25.0) 126 (28.1) 146 (32.6) 0.012 
NT-proBNP and CRP are displayed as median and 25th and 75th percentile. Other variables are shown as number 
(percentage of total) or as mean±SD where appropriate. P-Trend, p-value for trend across all tertiles; NYHA, 
New York Heart Association; BMI, body mass index; PCI, percutaneous coronary intervention; PTCA, 
percutaneous transluminal coronary angioplasty; CABG, coronary artery bypass grafting; LDL, low-density 
lipoprotein; HDL, high-density lipoprotein; ApoB, apolipoprotein B; ApoA-1, apolipoprotein A-1; eGFR, 
estimated glomerular filtration rate; CRP, C-reactive protein; NT-proBNP, amino-terminal pro-brain natriuretic 
peptide; ACE, angiotensin converting enzyme; ARB, angiotensin II receptor blocker. 
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Table 2.  Multivariable analysis of levels of baseline log-transformed standardized YKL-40 as a 
predictor of outcome in CORONA. 
YKL-40 Events HR (95% CI) p-value Wald C index, Δ NRI 
Primary end point     0.0011 (0.045) 0.07 (0.39) 
Unadjusted 383 1.30 (1.17-1.44) 0.000 24.7   
Step 1 383 1.21 (1.09-1.35)   0.000 13.1   
Step 2 382 1.18 (1.06-1.31) 0.003 9.08   
Step 3 295 1.03 (0.91-1.17) 0.613 0.26   
All-cause mortality      0.0001 (0.93) 0.09 (0.26) 
Unadjusted 396 137 (1.24-1.52) 0.000 37.2   
Step 1 396 1.27 (1.14-1.41) 0.000 20.3   
Step 2 395 1.23 (1.11-1.37) 0.000 15.3   
Step 3 306 1.07 (0.95-1.21) 0.263 1.25   
CV mortality     0.0002 (0.88) 0.08 (0.34) 
Unadjusted 319 1.39 (1.24-1.55) 0.000 31.8   
Step 1 319 1.28 (1.14-1.44) 0.000 17.9   
Step 2 318 1.24 (1.11-1.40) 0.000 13.3   
Step 3 245 1.10 (0.96-1.26) 0.19 1.74   
Death from WHF     0.0037 (0.29) 0.17 (0.61) 
Unadjusted 98 1.61 (1.30-1.98) 0.000 19.8   
Step 1 98 1.44 (1.16-1.79) 0.001 11.1   
Step 2 98 1.39 (1.12-1.73) 0.003 8.96   
Step 3 77 1.27 (0.98-1.64) 0.073 3.21   
Sudden death     0.0027 (0.021) 0.08 (0.44) 
Unadjusted 181 1.27 (1.09-1.47) 0.002 9.64   
Step 1 181 1.19 (1.02-1.38) 0.026 4.96   
Step 2 180 1.15 (0.98-1.34) 0.078 3.11   
Step 3 141 1.00 (0.84-1.20) 0.990 0.00   
Coronary end point     0.0011 (0.27) 0.05 (0.51) 
Unadjusted 304 1.20 (1.07-1.34) 0.002 9.85   
Step 1 304 1.15 (1.01-1.29) 0.019 5.46   
Step 2 301 1.13 (1.01-1.27) 0.040 4.22   
Step 3 233 1.05 (0.91-1.21) 0.492 0.47   
Hospitalization, any cause   0.0007 (0.016) 0.04 (0.53) 
Unadjusted 758 1.17 (1.09-1.26) 0.000 18.2   
Step 1 757 1.11 (1.03-1.19) 0.006 7.69   
Step 2 752 1.09 (1.01-1.17) 0.021 5.30   
Step 3 609 1.00 (0.92-1.09) 0.958 0.00   
Hospitalization, CV cause   0.0005 (0.56) 0.09 (0.34) 
Unadjusted 568 1.18 (1.09-1.28) 0.000 15.6   
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Step 1 567 1.14 (1.05-1.24) 0.002 9.67   
Step 2 564 1.13 (1.03-1.23) 0.006 7.53   
Step 3 463 1.03 (0.94-1.14) 0.492 0.47   
Hospitalization from WHF   0.0002 (0.75) 0.06 (0.47) 
Unadjusted 310 1.30 (1.16-1.46) 0.000 20.4   
Step 1 309 1.24 (1.11-1.39) 0.000 13.7   
Step 2 308 1.21 (1.08-1.36) 0.001 10.6   
Step 3 255 1.04 (0.91-1.19) 0.559 0.34   
 
YKL-40, log transformed per SD, as predictor of outcome. All Hazard Ratios (HR) are given as HR 
(95% confidence interval). C index, Δ; difference in C index between fully adjusted model with and 
without inclusion of YKL-40, corresponding (p-value). Net Reclassification Improvement (NRI); 
calculated from C-indexes for fully adjusted models with and without inclusion of YKL-40, 
corresponding (p-value). Unadjusted (n=1344). The models are adjusted as follows: Step 1 (n=1342): 
Ejection fraction, New York Heart Association functional class, age, body mass index, diabetes 
mellitus, sex, intermittent claudication and heart rate. Step 2 (n=1333): All variables from Step 1 as 
well as ApoB/Apo A-1 ratio and estimated glomerular filtration rate. Step 3 (1111): all variables from 
Step 2 as well as C-reactive protein and amino-terminal pro B-type natriuretic peptide. CV, 
cardiovascular; WHF, worsening heart failure. 
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Figure legends 
 
Figure 1 
Kaplan-Meier curves for the primary end point, coronary endpoint, all-cause- and CV mortality 
according to tertile of YKL-40 levels. T1, T2 and T3, represents tertile 1 to 3.  
 
Figure 2 
Interactions between treatment and serum levels of YKL-40 at baseline and association with outcomes 
in the CORONA trial. For each tertile (T1, T2 and T3) the fully adjusted HR and 95% CI is plotted. 
The p-values indicate the interaction by treatment term for each outcome (i.e. log-transformed 
standardized YKL-40*treatment). 
 
Figure 3 
Change in total cholesterol according to treatment and YKL-40 tertile. 
 
Figure 4 
Comparison with a previous study in HF. A. restricted cubic spline analysis of baseline YKL-40 
showing tertile (T1, T2 and T3) limits. B. Correlation between serum YKL-40 level using commercial 
enzyme immunoassay (EIA) from QUIDEL and R&D. C. Comparison of serum YKL-40 levels in our 
study divided into quartiles after normalizing the differences between the two EIA’s and the study by 
Harutyunyan et al.(14) D. Kaplan-Meier curves for the primary endpoint, coronary endpoint, all-
cause- and CV mortality according to quartiles of YKL-40.   
 
